<DOC>
	<DOCNO>NCT02762123</DOCNO>
	<brief_summary>The study conduct assess effect BMS-986142 single-dose PK parameter montelukast , flurbiprofen , omeprazole , midazolam , digoxin , probe drug ( cytochome P450 ) CYP2C8 , CYP2C9 , CYP2C19 , CYP3A4 , P-glycoprotein ( P-gp ) , respectively .</brief_summary>
	<brief_title>A Study Assess Effect BMS-986142 Pharmacokinetics ( PK ) Probe Substrates</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Flurbiprofen</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Signed Informed Consent 2 . Target population : Healthy ( current nonsmoker ) subject determine medical history , surgical history , physical examination , vital sign , electrocardiogram ( ECG ) , clinical laboratory determination . 3 . Subjects body mass index 18 32 kg/m2 , inclusive 4 . Men , woman nonchildbearing potential . Women must document proof childbearing potential must breastfeed . 5 . Males sexually active woman childbearing potential ( WOCBP ) must agree follow instruction method ( ) contraception duration treatment study drug ( ) plus 5 halflives study drug ( 3 day ) plus 90 day ( duration sperm turnover ) total 93 day ( approximately 14 week ) treatment completion . Female partner male subject expect use one highly effective method contraception list protocol . 1 . History chronic acute illness , recent infection , gastrointestinal disease , smoke alcohol abuse , significant drug allergy allergy digoxin , flurbiprofen , midazolam , omeprazole , montelukast , Bruton 's tyrosine kinase ( BTK ) inhibitor , immunologic related compound . 2 . History billiary disorder , asthma , bleed disorder , cancer 3 . Received live vaccine last 12 week , active tuberculosis ( TB ) last 3 year 4 . Medical history indicative increase risk arrhythmia . 5 . Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination beyond consistent target population .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>